Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:BGMS NASDAQ:TXMD NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.15-1.8%$2.39$1.65▼$3.07$23.08M0.2440,260 shs14,399 shsBGMSCyclacel Pharmaceuticals$0.78-14.1%$1.01$0.73▼$19.87$4.32M-0.46.97 million shs282,393 shsTXMDTherapeuticsMD$2.20+20.9%$2.05$0.98▼$2.95$25.46M0.644,498 shs259,099 shsVTGNVistaGen Therapeutics$0.58+0.5%$0.60$0.43▼$5.14$22.83M0.31572,138 shs677,771 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-1.83%-4.44%-4.44%-15.35%+11.40%BGMSCyclacel Pharmaceuticals-14.10%-47.88%-21.82%-5.27%+78,179,900.00%TXMDTherapeuticsMD+20.88%+10.55%+8.91%+1.38%+83.33%VTGNVistaGen Therapeutics+1.09%+5.94%-12.12%-5.12%-75.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.15-1.8%$2.39$1.65▼$3.07$23.08M0.2440,260 shs14,399 shsBGMSCyclacel Pharmaceuticals$0.78-14.1%$1.01$0.73▼$19.87$4.32M-0.46.97 million shs282,393 shsTXMDTherapeuticsMD$2.20+20.9%$2.05$0.98▼$2.95$25.46M0.644,498 shs259,099 shsVTGNVistaGen Therapeutics$0.58+0.5%$0.60$0.43▼$5.14$22.83M0.31572,138 shs677,771 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-1.83%-4.44%-4.44%-15.35%+11.40%BGMSCyclacel Pharmaceuticals-14.10%-47.88%-21.82%-5.27%+78,179,900.00%TXMDTherapeuticsMD+20.88%+10.55%+8.91%+1.38%+83.33%VTGNVistaGen Therapeutics+1.09%+5.94%-12.12%-5.12%-75.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 2.40Hold$9.83357.36% UpsideBGMSCyclacel Pharmaceuticals 1.00SellN/AN/ATXMDTherapeuticsMD 1.00SellN/AN/AVTGNVistaGen Therapeutics 1.80Reduce$0.9564.87% UpsideCurrent Analyst Ratings BreakdownLatest BGMS, TXMD, AYTU, and VTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026AYTUAytu BioPharma Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $14.506/3/2026VTGNVistaGen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/11/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/8/2026AYTUAytu BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/6/2026TXMDTherapeuticsMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)3/31/2026AYTUAytu BioPharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026BGMSCyclacel Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$66.38M0.35$0.38 per share5.73$2.11 per share1.02BGMSCyclacel Pharmaceuticals$750K5.75N/AN/A$1.40 per share0.56TXMDTherapeuticsMD$3.02M8.43$0.05 per share47.15$2.32 per share0.95VTGNVistaGen Therapeutics$490K46.59N/AN/A$2.44 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$13.56M-$4.58N/A8.60N/A-60.17%-69.93%-13.25%N/ABGMSCyclacel Pharmaceuticals-$3M-$4.54N/AN/AN/AN/A-51.21%-44.00%N/ATXMDTherapeuticsMD-$570K$0.0636.67N/AN/A5.34%0.32%0.23%8/17/2026 (Estimated)VTGNVistaGen Therapeutics-$51.42M-$1.89N/AN/AN/AN/A-109.72%-89.62%6/16/2026 (Estimated)Latest BGMS, TXMD, AYTU, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2026Q4 2026VTGNVistaGen Therapeutics-$0.3377N/AN/AN/A$0.40 millionN/A6/16/2026Q4 2026VTGNVistaGen Therapeutics-$0.3367N/AN/AN/A$0.40 millionN/A5/15/2026Q1 2026BGMSCyclacel PharmaceuticalsN/A-$0.04N/A-$0.04N/AN/A5/13/2026Q3 2026AYTUAytu BioPharma-$0.4433-$0.53-$0.0867-$0.53$12.05 million$12.41 million5/12/2026Q1 2026TXMDTherapeuticsMD-$6.1250$0.01+$6.1350$0.01$19.77 million$0.72 million3/30/2026Q4 2025BGMSCyclacel PharmaceuticalsN/A-$2.21N/A-$2.21N/A$0.67 million3/30/2026Q4 2025TXMDTherapeuticsMD-$6.1250-$0.0530+$6.0720-$0.05$19.77 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ABGMSCyclacel PharmaceuticalsN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.121.00BGMSCyclacel PharmaceuticalsN/A7.065.87TXMDTherapeuticsMDN/A3.113.11VTGNVistaGen TherapeuticsN/A4.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%BGMSCyclacel Pharmaceuticals23.58%TXMDTherapeuticsMD30.74%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma4.90%BGMSCyclacel Pharmaceuticals23.75%TXMDTherapeuticsMD1.70%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma16010.73 million10.21 millionNot OptionableBGMSCyclacel Pharmaceuticals145.52 million4.21 millionN/ATXMDTherapeuticsMD42011.57 million11.38 millionOptionableVTGNVistaGen Therapeutics4039.62 million38.49 millionOptionableBGMS, TXMD, AYTU, and VTGN HeadlinesRecent News About These CompaniesVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderJune 9, 2026 | businesswire.comVistaGen Therapeutics (VTGN) to Release Earnings on TuesdayJune 9, 2026 | americanbankingnews.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmJune 1, 2026 | prnewswire.comVistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerMay 19, 2026 | businesswire.comIs Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?May 19, 2026 | insidermonkey.comVistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderMay 12, 2026 | businesswire.comVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderMay 8, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmApril 29, 2026 | globenewswire.comVistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock DropApril 28, 2026 | prnewswire.comVistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseApril 22, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmApril 20, 2026 | newsfilecorp.comNVistaGen Faces Nasdaq Audit Committee Compliance SetbackApril 2, 2026 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGNMarch 17, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMarch 16, 2026 | globenewswire.comCLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline TonightMarch 16, 2026 | businesswire.comVTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud LawsuitMarch 16, 2026 | prnewswire.comVTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMarch 16, 2026 | prnewswire.comVistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGNMarch 16, 2026 | prnewswire.comVTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNMarch 15, 2026 | newsfilecorp.comNVTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026March 15, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBGMS, TXMD, AYTU, and VTGN Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.15 -0.04 (-1.83%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.21 +0.06 (+2.79%) As of 06/12/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Cyclacel Pharmaceuticals NASDAQ:BGMS$0.78 -0.13 (-14.10%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.76 -0.03 (-3.30%) As of 06/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.TherapeuticsMD NASDAQ:TXMD$2.20 +0.38 (+20.88%) As of 06/12/2026 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.VistaGen Therapeutics NASDAQ:VTGN$0.58 +0.00 (+0.54%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.59 +0.02 (+3.09%) As of 06/12/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
